dual glp 1 and gip receptor agonist Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Dual GLP-1/GIP receptor agonists mechanism

95% CI 0.90, 1.01) and cerebrovascular events (HR 0.99

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

GLP-1 (glucagon-like peptide-1) is a hormone that plays a crucial role in regulating blood sugar levels and appetite

Appetite and craving support

Discover cost-effective, personalized weight loss solutions

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials